

Pan Cancer




Supplemental Figure 1. Trends of genomic alterations are confirmed in a greater cohort of 176 Pan Cancer studies (n=46697).

Supplemental Figure 1




Supplemental Figure 2. Genomic dysregulation of tumor suppressor or oncogenes in cancers. Deletions (blue) and truncation mutations (black) for tumor suppressor genes and amplifications (red) and oncogenes are shown in (A) 32 TCGA Pan Cancer studies (n=10967) as well as (B) 176 Pan Cancer studies (n=46697).

Supplemental Figure 2




Supplemental Figure 3. Genomic dysregulation of cardiac myosin heavy chain MYH6 and MYH7 genes in cancer. **(A)** MYH6 and MYH7 genes are co-amplified or deleted in the same tumor samples (n=46697); **(B)** MYH6 and MYH7 genes are recurrently mutated in cancer (n=46697). To visualize mutations in these genes, we examined changes throughout the gene with the x-axis representing the amino acid number and the y-axis represents the total mutation counts at a specific residue. 960 mutations were observed in MYH6 while 1081 mutations for observed in MYH7. Missense (green) and truncation (black) mutations are shown. Truncation mutations are frequent and distributed throughout the two genes.

Supplemental Figure 3



Supplemental Figure 4. Copy number variations of ACTA1 are observed in cancers (176 Pan Cancer studies). ACTA1, located next to MDM4 at 1q42.13, is amplified independent of MDM4 in limited patient tumor samples (black box).

Supplementary Figure 4



Supplemental Figure 5. Kaplan-Meier curve for NPLOC4 in UCEC. The altered group represents overall gain, including amplification and overexpression.

Supplementary Figure 5

Supplementary Table 1. Genomic location of nine myosin and actin genes of interest.

Gene	MYL2	MYL3	МҮН7	МҮН6	MYLK2	MYLK3	ACTC1	ACTA1	ACTG1
		,			Myosin Light	Myosin Light	Actin Alpha 1	Actin Alpha 1,	Actin Gamma 1
Name	Chain 2	Chain 3	Chain 7	Chain 6	Chain Kinase 2	Chain Kinase 3	Cardiac Muscle	Skeletal Muscle	Cytoplasmic
Genomic									
ocation	12q24.11	3p21.31	14q11.2	14q11.2	20q11.21	16q11.2	15q14	1q42.13	17q25.3

Supplementary Table 2. Hallmark gene set ranking based on GSEA analysis of *ACTG1* gains in UCEC. Pathways are ranked by NES (Net Enrichment Score).

UCE	C		
Hallmark Gene Set	NES	FDR	
Interferon Gamma Response	-2.033	0	
KRAS Signaling (Down)	2.14	0	
Apical Junction	2.214	0	
Myogenesis	2.2559	0	
Allograft Rejection	-1.9148	0.0009	
MYC Targets (V2)	1.8584	0.0009	
Interferon Alpha Response	-1.8716	0.001	
Epithelial Mesenchymal Transition	1.8687	0.0011	
Protein Secretion	-1.829	0.0015	
Cholesterol Homeostasis	1.8063	0.0018	
Androgen Response	-1.6895	0.0065	
Apical Surface	1.6405	0.0075	
UV Response (UP)	1.561	0.0142	
Hypoxia	1.5618	0.016	
Estrogen Response (Late)	1.5198	0.019	
IL6 JAK STAT3 Signaling	-1.4886	0.0402	
KRAS Signaling (Up)	-1.429	0.0611	
Coagulation	1.3776	0.0614	
Glycolysis	1.3462	0.0743	
Fatty Acid Metabolism	-1.3571	0.0765	
Pancreas Beta Cells	-1.3633	0.0795	
Complement	-1.3689	0.0841	
Inflammatory Response	-1.3804	0.0851	

Supplementary Table 3. Hallmark gene set ranking based on GSEA analysis of *ACTG1* gains in UCS. Pathways are ranked by NES (Net Enrichment Score).

UCS				
Hallmark Gene Set	NES	FDR		
Interferon Gamma Response	-2.5541	0		
Allograft Rejection	-2.3693	0		
Interferon Alpha Response	-2.3287	0		
Myogenesis	-2.268	0		
IL6 JAK STAT3 Signaling	-2.2616	0		
Inflammatory Response	-2.1501	0		
Complement	-1.9128	0.0001		
IL2 Stat5 Signaling	-1.7256	0.003		
Xenobiotic Metabolism	-1.597	0.0102		
Apical Surface	-1.5643	0.0144		
Epithelial Mesenchymal Transition	-1.4791	0.0348		
KRAS Signaling (Up)	-1.4572	0.0364		
Adipogenesis	-1.4587	0.0385		
Apoptosis	-1.444	0.0388		
TNFA Signaling (Via NFKB)	-1.4121	0.0489		
Estrogen Response Early	-1.3866	0.0606		
Pancreas Beta Cells	-1.3791	0.0612		

Supplementary Table 4. Oncogenic signaling program rankings based on GSEA analysis of *ACTG1* gains in UCEC and UCS.

Oncogenic Signaling Programs. C6	UCS-NES	UCS-FDR	UCEC-NES	UCEC-FDR
RPS14_DN.V1_UP	-1.993	0.000	-1.851	0.000
LTE2_UP.V1_DN	-1.754	0.006	-1.884	0.000
BMI1_DN.V1_UP	-1.713	0.009	1.923	0.001
HOXA9_DN.V1_UP	-1.661	0.011	-2.127	0.000
MEK_UP.V1_DN	-1.615	0.015	-2.278	0.000
STK33_SKM_UP	-1.579	0.015	-2.329	0.000
LEF1_UP.V1_UP	-1.588	0.014	1.893	0.001
LEF1_UP.V1_DN	-1.592	0.017	-1.862	0.000
MEL18_DN.V1_UP	-1.646	0.013	1.447	0.030
KRAS.50_UP.V1_DN	1.558	0.049	2.103	0.000
ATF2_UP.V1_UP	-1.452	0.049	1.926	0.001
AKT_UP.V1_DN	-1.569	0.015	1.401	0.041
EIF4E_DN	-1.427	0.062	-1.762	0.001
GCNP_SHH_UP_LATE.V1_DN	-1.390	0.077	2.021	0.000
KRAS.BREAST_UP.V1_DN	-1.419	0.062	1.547	0.018
KRAS.LUNG.BREAST_UP.V1_DN	1.357	0.083	1.800	0.003
JAK2_DN.V1_DN	1.364	0.089	-1.879	0.000
PRC1_BMI_UP.V1_DN	1.560	0.097	1.857	0.001
BCAT_GDS748_UP	-1.590	0.015	-1.393	0.088
KRAS.BREAST_UP.V1_UP	-1.372	0.082	1.512	0.022
ESC_J1_UP_LATE.V1_UP	-1.680	0.013	1.282	0.099
KRAS.PROSTATE_UP.V1_DN	1.369	0.100	1.412	0.040
CORDENONSI_YAP_CONSERVED_SIGNATURE	-1.401	0.074	1.295	0.093

Supplementary Table 5. Categorization of *ACTG1* dependent and non-dependent cell lines in uterine cancer.

Dependent Cell Lines					
Cell Line	Lineage Subtype	Primary/Metastasis			
KLE	Endometrial Adenocarcinoma	Primary			
HEC6	Endometrial Adenocarcinoma	Primary			
EN	Endometrial Adenocarcinoma	Primary			
ESS1	Endometrial Stromal Sarcoma	Primary			
SNGM	Endometrial Adenocarcinoma	Metastasis			
HEC50B	Endometrial Adenocarcinoma	Metastasis			
HEC251	Endometrial Adenocarcinoma	Primary			
JAR	Choriocarcinoma	Primary			
MFE319	Endometrial Adenocarcinoma	N/A			
SNU685	Carcinosarcoma	Primary			
JHUEM7	Endometrial Adenocarcinoma	Primary			
Non-Dependent Cell Lines					
Cell Line	Lineage Subtype	Primary/Metastasis			
TEN	Clear Cell Carcinoma	Primary			
HEC59	Endometrial Adenocarcinoma	Primary			
HEC1B	Endometrial Adenocarcinoma	Primary			
JHUEM1	Endometrial Adenocarcinoma	Primary			
SNU1077	Carcinosarcoma	Primary			
RL952	Endometrial Adenosquamous	Primary			
HEC265	Endometrial Adenocarcinoma	Primary			
SKGI	Endometrial Squamous	Primary			